Posted by Michael Wonder on 30 May 2021
Diurnal receives European Commission approval for Efmody
28 May 2021 - Commercial launch anticipated in Q3 2021.
Diurnal Group announces the European Commission has approved the marketing authorisation for Efmody (hydrocortisone modified-release hard capsules – development name Chronocort) as treatment of adult and adolescent patients (12 years and older) with the rare condition congenital adrenal hyperplasia.
This decision by the European Commission follows the positive opinion issued by the EMA in March 2021.
